Recursion
@recursionpharma.bsky.social
860 followers 6 following 180 posts
Decoding biology to radically improve lives. The industrial revolution of drug discovery is here. Learn more at recursion.com #techbio
Posts Media Videos Starter Packs
recursionpharma.bsky.social
Inside the AI transformation of drug discovery.
On Oct. 15 on the Main Stage of GITEX Global at the Dubai World Trade Center, Recursion cofounder & CEO Chris Gibson will give a keynote on "AI, Data & DNA: TechBio’s Disruption of Drug Discovery." 👉 visit.gitex.com
#GITEXGlobal #GITEX2025 #TechBio
recursionpharma.bsky.social
Announcing TechBio Talks Episode 2: A deep dive into phenomics, open science and virtual cells.

Host Chris Gibson talks to the Broad Institute's Anne Carpenter, a pioneer in image-based profiling, who played a key role in Recursion’s origin story. 🧵
recursionpharma.bsky.social
In a clip from our podcast TechBio Talks, MIT's Regina Barzilay tells host Najat Khan how we can leverage machine learning to better predict how a patient will respond to treatments, to improve his or her condition for the “longest time with minimal side effects.” www.youtube.com/shorts/uSEM1... 🧵
Using Machine Learning to Predict Patient Response to Treatment
YouTube video by Recursion
www.youtube.com
recursionpharma.bsky.social
Driving this industry-defining innovation takes bold, bilingual thinkers who collaborate across disciplines, and push back against the status quo.

If this sounds like your kind of mission, we're hiring. www.recursion.com/careers

👉See the list: www.fastcompany.com/best-workpla...
Careers at Recursion: Join Our Mission | Recursion
Embark on a career journey with Recursion. Dive into opportunities, culture, and the impact you can make. Apply to work with us today!
www.recursion.com
recursionpharma.bsky.social
We♥️our innovators.

Recursion was recognized as one of the “Best Workplaces for Innovators” by @fastcompany.com.

At Recursion, we're building a new kind of drug discovery & development platform from the ground up – relentlessly working toward a better way to bring new medicines to patients. 🧵
recursionpharma.bsky.social
Maintaining our sense of urgency, because patients are waiting.

In a clip from the latest installment in our internal #RXU series – Chief R&D Officer and Chief Commercial Officer Najat Khan talks about the importance of urgency. #TechBio
recursionpharma.bsky.social
A recent story in @reuters.com looks at momentum happening in #AI drug discovery, noting that AI adoption across the #pharma industry will lead to “faster and cheaper results” including through reduction in animal testing, a recent push from the #FDA. More: www.reuters.com/business/hea...
recursionpharma.bsky.social
“We’re focused on going places that we don’t think other people can.” On 9/8, Chris Gibson & Najat Khan presented at the Morgan Stanley Global Healthcare Conference, addressing macro concerns, platform evolution & what we anticipate from partnership milestones
👉 event.webcasts.com/viewer/event...
recursionpharma.bsky.social
A new feature in @financialtimes.com looks at what’s needed for #AI drug discovery to begin delivering on its promises and how the latest #ML breakthroughs paired with over a decade of fit-for-purpose data generation has positioned us for that moment.
👉 www.ft.com/content/9a8a...
recursionpharma.bsky.social
🌄 The peak is now the basecamp.

A new feature in @pharmaphorum.bsky.social looks at how Recursion has built the necessary foundation & is now accelerating into a new era of AI-led drug discovery, focused on delivering transformative, first-in-class medicines. pharmaphorum.com/deep-dive/ai...
recursionpharma.bsky.social
In an interview with Occam, Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan outlines the strategy for building a #TechBio company that’s positioned to win.

👉 Read more: www.occam-global.com/blogs/an-int...
Read Occam's interview with AIDD leader Najat Khan, PhD. | Occam Global
Read Occam's interview with AIDD leader Najat Khan, PhD.
www.occam-global.com
recursionpharma.bsky.social
🎉 Daniel Cohen, President of Valence Labs (@valenceai.bsky.social),
Recursion’s AI research engine, has been named a “Rising Leader” by Citeline. #TechBio #AI #ML #research #virtualcell

👉Read more: insights.citeline.com/in-vivo/lead...
recursionpharma.bsky.social
📣 The inaugural episode of TechBio Talks is now live!
Host Najat Khan sits down w/ MIT Distinguished Professor Regina Barzilay for a fascinating conversation about the new AI technologies transforming healthcare.

▪️ Spotify: open.spotify.com/show/2bjoBPs...
▪️ YouTube: youtube.com/playlist?lis...
recursionpharma.bsky.social
🔹 Join us in September as Recursion executives present at two upcoming investor conferences:

▪️ Sept. 3: Citi 2025 BioPharma Back to School Conference

▪️ Sept. 8: Morgan Stanley 23rd Annual Global Healthcare Conference

👉 Learn more and tune in here: ir.recursion.com.

#investor #IR #IRconference
recursionpharma.bsky.social
🎙️ Introducing #TechBio Talks – a new podcast hosted by Chris Gibson & Najat Khan offering candid conversations with the scientists, founders, & investors on the frontlines of #AI drug discovery. Subscribe now:
▪️ Spotify: open.spotify.com/show/2bjoBPs...
▪️ YouTube: www.youtube.com/playlist?lis...
recursionpharma.bsky.social
🔹 Delivering breakthroughs, at scale. Last week, Erik Douglas, VP of Product, joined some of the biggest names in tech – including Fei-Fei Li and Geoffrey Hinton – at the #Ai4 conference in Vegas where he provided insights into our AI-driven industrialization of drug discovery and development.
recursionpharma.bsky.social
An article in BioPharmaTrend highlighted our recent earnings report, including “progress on internal assets REC-1245 (RBM39 degrader) and REC-617 (CDK7 inhibitor), alongside a $7 million milestone payment from Sanofi for a partnered immunology program.” www.biopharmatrend.com/news/recursi...
recursionpharma.bsky.social
In a new series called "Explain the Impact," Chase Neumann, Associate Director of Oncology, shares how we used the Recursion OS to discover new ways to target aggressive cancers and identify biomarkers that can better guide patient selection and improve outcomes. www.youtube.com/shorts/33ltb...
Using Data & AI to Deliver a New Cancer Drug to Clinic Twice as Fast as Industry Average
YouTube video by Recursion
www.youtube.com
recursionpharma.bsky.social
💡 “It’s not a taller ladder, it’s an elevator.”

In this video, Lina Nilsson, PhD, Chief Platform Officer, shares what we mean by industrialization at Recursion. The video is part of our internal RXU learning platform which provides deep dives into our mindset, mission, and value drivers. #TechBio
recursionpharma.bsky.social
Anne Carpenter spoke at @mit.edu about the importance of #biology imaging in the age of #AI. Using phenotypic maps, she says, Recursion has “identified thousands of screenable image phenotypes & hundreds of potential therapeutics & launched multiple clinical trials.” www.youtube.com/watch?v=kP-G...
recursionpharma.bsky.social
🚀 A new article from CURE looks at how open-source datasets & tools like Boltz-2 are “unlocking powerful capabilities once limited to Big Pharma,” allowing startups & researchers to “dramatically accelerate & de-risk R&D involved in discovering new medicines.” wewillcure.com/insights/the... #techbio
recursionpharma.bsky.social
In a new paper in @acs.org Infectious Diseases, Recursion scientists look at how #AI & automation are helping to tackle ongoing challenges in global public health by:
▪️ generating hypotheses
▪️ overcoming data scarcity
▪️ streamlining clinical trials

Read more: www.recursion.com/news/using-a...
Using AI and Automation to Improve Outcomes in Infectious Diseases
www.recursion.com